Comparison · NCT00819052-1de1ca1a
Nevirapine Immediate Release (NVP IR) vs Nevirapine Extended Release (NVP XR): Occurence of Hepatic Events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Nevirapine Immediate Release (NVP IR) vs Nevirapine Extended Release (NVP XR): Occurence of Hepatic Events. Trial comparisons, record NCT00819052-1de1ca1a. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00819052-1de1ca1a
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0 | 0 | 0.0253 | wilson | |
| Risk in group 2 | 0.00339 | 0.000599 | 0.0189 | wilson | |
| Risk difference, group 1 minus group 2 | -0.00339 | -0.0189 | 0.0221 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | log | a group has no participants with the outcome | |||
| Odds ratio, group 1 over group 2 | log | a cell of the two-by-two table is zero | |||
| Number needed to treat, for one fewer participant with the outcome on Nevirapine Immediate Release (NVP IR) than on Nevirapine Extended Release (NVP XR) | 295 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Nevirapine Immediate Release (NVP IR) | Nevirapine immediate release 200 mg tablets given twice daily | 0 | 148 | OG000 |
| Group 2 | Nevirapine Extended Release (NVP XR) | Nevirapine extended release 400 mg tablets given once daily | 1 | 295 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Occurence of Hepatic Events
- Description
- Time frame
- 144 weeks
- Population
- Full Analysis Set (FAS) includes all participants randomized to treatment and confirmed to have taken at least one dose of treatment.
Source ClinicalTrials.gov
Trial
- Title
- Switching Nevirapine Immediate Release( IR) Based Regimen to Nevirapine Extended Release (XR) Based Regimen in Human Immunodeficiency Virus One (HIV-1) Infected Patients
- NCT number
- NCT00819052
- Phases
- PHASE3
- Conditions
- HIV Infections
- Interventions
- Nevirapine XR, Nevirapine XR, Nevirapine IR
- Lead sponsor
- Boehringer Ingelheim
- Results first posted
- 2012-02-24
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00819052?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00819052-1de1ca1a